Amedco - Quiz

New Frontiers in Intestinal Failure-ENDURING MOC


A   - It is produced by L-cells found in the ileum and cecum.
B   - GLP-2 is a potent intestinotrophic hormone which increases crypt cell proliferation, and visceral blood flow and decreases gastro-intestinal motility and gastric secretions.
C   - Neuroendocrine cells, myofibroblasts and enteric neurons have GLP-2 receptors.
D   - GLP-2 is inactivated by dipeptidyl dipeptidase and has a relatively long half-life.

A   - It is identical to native GLP-2 except for a substitution of alanine by glycine at second position of N-terminus, resulting in an extended T½.
B   - It was approved in 2012 by the United States FDA for adults with short-bowel syndrome who are dependent on parenteral nutrition, and may be associated with improved absorption and decreased parenteral nutrition needs.
C   - It can be associated with side effects including but not limited to abdominal pain, nausea, and gastrointestinal stomal complications.
D   - All of the above are true.

A   - Low mead acid
B   - Elevated mead acid
C   - Low linoleic acid
D   - Low alpha linolenic acid
E   - B, C and D

A   - Reduction in the incidence of NEC
B   - Mortality rate for all causes of short gut
C   - Median duration of parenteral needs in short gut
D   - Percentage of patients achieving enteral autonomy.

A   - Reduces graft salvage four fold if they persist after transplant
B   - Is ominous if they appear prior to transplant
C   - Has no effect upon outcomes
D   - Is more likely to persist in patients undergoing combined liver bowel transplant than in patients undergoing isolated bowel transplant.

A   - True
B   - False